Antileishmanial agent-13 

Antileishmanial agent-13 is a quinoline-isatin hybrid, acts as an antileishmanial agent against L. Major Leishmania strain. Antileishmanial agent-13 acquires the antileishmanial activity via the anti-folate mechanism. Antileishmanial agent-13 has potent inhibition against both promastigote and amastigote forms with IC₅₀s of 0.604 μM and 0.508 μM, respectively^[1].

Antileishmanial agent-13 (compound 4e) shows promising in vitro activity against the promastigote superior to Miltefosine (HY-13685) (IC₅₀=7.8976 µM)^[1].
Antileishmanial agent-13 (2 μM; 48 h) shows antileishmanial activity mostly attributing to the anti-folate mechanism, via inhibiting DHFR-TS and PTR1^[1].
Antileishmanial agent-13 (0-100 μM; 72 h) has low cytotoxicity against African green monkey kidney cells (VERO cells) with CC50 value of 155.8 μM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

401.64

C₁₇H₁₀BrClN₄O

853725-86-7

O=C1NC2=C(/C1=N\NC3=CC=NC4=CC(Cl)=CC=C43)C=C(C=C2)Br

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sabt A, et al. New antileishmanial quinoline linked isatin derivatives targeting DHFR-TS and PTR1: Design, synthesis, and molecular modeling studies[J]. European Journal of Medicinal Chemistry, 2022: 114959.